Biopharmaceutical start-up TwoXar has raised $10m to develop its AI system, which is aimed at reducing the cost and time needed to identify new drugs. TwoXar, a biopharmaceutical startup that uses artificial intelligence (AI) to identify and develop new medicines, has raised $10 million in a series A round of funding led by SoftBank’s early-stage venture capital firm, SoftBank Ventures, with participation from Andreessen Horowitz and Braintree founder Bryan Johnson’s OS Fund. The California-based company uses cloud computing and big data rather than lab-based approaches and said its system means drugs can be ready for first-stage testing in weeks rather than years. The series A funding was led by SoftBank Ventures. Andreessen Horowitz and OS Fund also took part. “Artificial intelligence will change how we do business as a society,” says David Sacks, co-founder of OneLogin, an online identity management company.
Biopharmaceutical start-up TwoXar has raised $10m to develop its AI system, which is aimed at reducing the cost and time needed to identify new drugs. The California-based company uses cloud computing and big data rather than lab-based approaches and said its system means drugs can be ready for first-stage testing in weeks rather than years. The series A funding was led by SoftBank Ventures. Andreessen Horowitz and OS Fund also took part. “Artificial intelligence will change how we do business as a society,” says David Sacks, co-founder of OneLogin, an online identity management company.